On February 14^th, 2025, the Phase I clinical trial for ZHB110 sublingual tablets—a Class 1 new biologic drug for treatment, independently developed by Zonhonbio with full intellectual property rights in China and abroad was officially initiated at Beijing Tongren Hospital, Capital Medical University.

As the sponsor, Zonhonbio launched the study titled "Safety and Tolerability of ZHB110 Sublingual Tablets in Adult Subjects with Artemisia Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis (With or Without Allergic Asthma)." The trial is led by Professor Luo Zhang, President of Beijing Tongren Hospital, Capital Medical University, serving as the Principal Investigator (PI). The study aims to evaluate the safety and tolerability of ZHB110 sublingual tablets in participants following administration.

Allergen-specific immunotherapy (AIT), also known as desensitization therapy, is currently the only treatment modality considered capable of modifying the progression of allergic diseases. ZHB110 is a novel sublingual desensitization formulation (featuring controllable dosing, excellent storage stability, and convenient administration). By dissolving under the tongue, it induces immune tolerance, thereby altering the natural course of allergic diseases and providing long-term symptom relief. This innovative therapy offers a new treatment option for patients allergic to Artemisia pollen, significantly improving their quality of life.